Role of the Purinergic P2Y2 Receptor in Pulmonary Hypertension

Int J Environ Res Public Health. 2021 Oct 20;18(21):11009. doi: 10.3390/ijerph182111009.

Abstract

Pulmonary arterial hypertension (PAH), group 1 pulmonary hypertension (PH), is a fatal disease that is characterized by vasoconstriction, increased pressure in the pulmonary arteries, and right heart failure. PAH can be described by abnormal vascular remodeling, hyperproliferation in the vasculature, endothelial cell dysfunction, and vascular tone dysregulation. The disease pathomechanisms, however, are as yet not fully understood at the molecular level. Purinergic receptors P2Y within the G-protein-coupled receptor family play a major role in fluid shear stress transduction, proliferation, migration, and vascular tone regulation in systemic circulation, but less is known about their contribution in PAH. Hence, studies that focus on purinergic signaling are of great importance for the identification of new therapeutic targets in PAH. Interestingly, the role of P2Y2 receptors has not yet been sufficiently studied in PAH, whereas the relevance of other P2Ys as drug targets for PAH was shown using specific agonists or antagonists. In this review, we will shed light on P2Y receptors and focus more on the P2Y2 receptor as a potential novel player in PAH and as a new therapeutic target for disease management.

Keywords: pharmacological approach; pulmonary arterial hypertension; purinergic P2Y2 receptor.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Endothelial Cells
  • Humans
  • Hypertension, Pulmonary*
  • Pulmonary Artery
  • Receptors, Purinergic
  • Receptors, Purinergic P2Y2

Substances

  • Receptors, Purinergic
  • Receptors, Purinergic P2Y2